In after-hours trade Tuesday, Supernus Pharmaceuticals (SUPN) shares soared more than 24% percent to $27.99, following the firm revealed promising findings from a trial of its new treatment for attention deficit hyperactivity disorder, or ADHD. Supernus reported Tuesday afternoon that its intended goal was met in a phase 3 trial of the medication, known as SPN-812, in adults.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
The Food and Drug Administration is actively reviewing the drug for use in children aged 6 to 17, and once it is approved by the FDA, Supernus plans to ask that the drug be considered for adults as well.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares surged more than 40% as trades resumed after the end of after-hours trading Tuesday afternoon, but gradually declined to around 20 percentsurge by the end of the extended session.
Read More
